Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Medigene (0QGJ – Research Report) and keeping the price target at €2.00.
Joseph Pantginis has given his Buy rating due to a combination of factors including Medigene’s strategic partnership with EpimAb Biotherapeutics. This collaboration is aimed at advancing next-generation TCR-TCEs for immune-related disorders, which is a promising step in Medigene’s efforts to innovate within the field of TCR technology. The partnership leverages Medigene’s expertise in TCR development alongside EpimAb’s proprietary platforms, which could lead to the creation of bispecific antibodies with enhanced targeting capabilities and reduced off-target effects.
Additionally, Medigene’s progress with its MDG1015 program, particularly the recent CTA submission to the EMA for treating multiple solid tumors, underscores its potential for clinical advancement. The program’s innovative manufacturing process, which includes a shortened cell expansion period, aims to optimize cell quality and reduce treatment times, potentially improving clinical outcomes in terms of efficacy, durability, and safety. These developments collectively support the positive outlook and Buy rating assigned by Pantginis.
According to TipRanks, Pantginis is an analyst with an average return of -5.2% and a 29.38% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Viking Therapeutics, and Esperion.